The acquisition also includes the controlled release technology of Ibuprofen 12-hour extended release OTC, the company said in a statement.
"The acquisition complements Shasun's strategy to expand its range of non-steroidal anti-inflammatory drug (NSAIDS) products through novel, safe and efficacious technologies, including applications across its Ibuprofen franchise," it said.
Commenting on the move, Shasun Pharmaceuticals managing director S Abhaya Kumar said: "The acquisition is the first among a series of strategic initiatives in our quest to continue to enhance our global leadership in the NSAIDS category."
Shashun is among top vertically integrated manufacturers of Ibuprofen and its derivatives, from actives to formulated packaged products for both prescription and over-the-counter markets.
Shares of Shashun Pharmaceuticals were trading at Rs. 129.45 per scrip in the afternoon trade, up 1.33 per cent from the previous close on the BSE